Form 4: Korro Bio's Chief Operating Officer, Todd Chappell, Reports Stock Option Grant
SEC Form 4 Filing
Todd Chappell, Chief Operating Officer of Korro Bio, Inc., reports the acquisition of stock options.
Summary
- Todd Chappell, the Chief Operating Officer of Korro Bio, Inc., filed a Form 4 on February 5, 2025, reporting a transaction that occurred on February 3, 2025.
- The transaction involves the acquisition of stock options for 34,500 shares of common stock at an exercise price of $33.50.
- These options vest in 48 equal monthly installments starting February 3, 2025, contingent upon continued service.
- Chappell also granted a Limited Power of Attorney to Ram Aiyar, Vineet Agarwal, Jeffrey Cerio, and Oliver Dolan to handle SEC filings on his behalf.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the executive's continued contribution to the company. There are no negative indicators in the filing.
Positives
- The granting of stock options to the COO aligns his interests with those of the shareholders.
- The vesting schedule encourages continued service and commitment from the COO.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service from the COO.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant aligns with standard compensation practices in the sector.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their executives.
- The size of the grant is likely benchmarked against similar roles and company size within the biotech sector.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with theirs.
- Employees may see this as a sign of stability and investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of the stock option transaction and start of vesting period. |
| 02/04/2025 | Date of execution of the Power of Attorney. |
| 02/05/2025 | Date of filing the Form 4. |
| 02/02/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.